A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5565-5570

  Raz, Dan J ^a,e   Ray, M Roshni ^a   Kim, Jaey Y ^a   He, Biao ^a   Taron, Miquel ^b   Skrzypski, Marcin ^c   Segal, Mark ^a   Gandara, David R ^d   Rosell, Rafael ^b   Jablons, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN KINASE LCK; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN 3; UNCLASSIFIED DRUG; WNT3A PROTEIN;

AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE NUMBER; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; TUMOR VOLUME; ADENOCARCINOMA; COMPARATIVE STUDY; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; RISK; SURVIVAL; VALIDATION STUDY;

ADENOCARCINOMA; AGED; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK; SURVIVAL ANALYSIS;

EID: 53049103290     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0544     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer 2000;89:2334-44.
3. Harpole DH, Jr., Herndon JE II, Young WG, Jr., Wolfe WG, Sabiston DC, Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350: 351-60.
5. WintonT, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
6. Thunnissen FB, Schuurbiers OC, den Bakker MA. A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 2006;48:779-86.
7. Brundage MD, Davies D, Mackillop WJ.Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
8. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
9. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
10. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.
11. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-72.
12. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-8.
13. Wang Y, Barbacioru C, Hyland F, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006;7:59.
14. Chen HY,Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
15. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-9.
16. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
17. Miura K, Bowman ED, SimonR,et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002;62:3244-50.
18. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000;83:473-9.
19. Park M, HastieT. An L1 regularization-path algorithm for generalized linear models. Journal of the Royal Statistical Society 2007;69:659-77.
20. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society 2006;58:267-88.
21. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Annals of Statistics 2004;32:407-99.
22. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. New York: Springer-Verlag; 2001.
23. Gui J, Li H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bio-informatics 2005;21:3001-8.
24. Segal MR. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. Biostatistics 2006;7:268-85.
25. Team RDC. R: A language and environment for statistical computing. 2.3.1 ed. Vienna, Austria: R Foundation for Statistical Computing; 2006.
26. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
27. Muller-Tidow C, Diederichs S, Bulk E, et al. Identifi-cation of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res2005;65:1778-82.
28. Inngjerdingen M, Torgersen KM, Maghazachi AA. Lck is required for stromal cell-derived factor 1 α (CXCL12)-induced lymphoid cell chemotaxis. Blood 2002;99:4318-25.
29. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett 2005;222:1-10.
30. Bektic J, Pfeil K, BergerAP, et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005;64:332-40.
31. McDoniels-Silvers AL, Stoner GD, Lubet RA,You M. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002;4:141-50.
32. Raz DJ, Glidden DV, Odisho AY, Jablons DM. Clinical characteristics and survival of patients with surgically resected incidentally detected lung cancer. J Thorac Oncol 2007;2:125-30.